Loading...
Market
Bristol Myers' CAR-T market share by 2026
5
Resolution / Starting Odds
Below 15% • 25%
15% to 30% • 25%
30% to 45% • 25%
Above 45% • 25%
Market research reports and financial disclosures from Bristol Myers Squibb.
Story
Bristol Myers, Cellares Ink $380M Deal to Boost CAR-T Therapy Production
Apr 22, 2024, 01:01 PM
Bristol Myers Squibb has signed a significant $380 million agreement with Cellares to enhance the production and supply of CAR-T cell therapies. This partnership aims to extend the reach of these therapies to more patients across the United States, European Union, and Japan. The deal involves Cellares acting as a contract manufacturer to help meet the growing demand for these innovative treatments.
View original story
Similar markets
Below 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Above 75% • 25%
Less than 20% • 20%
20% to 35% • 20%
36% to 50% • 20%
51% to 65% • 20%
More than 65% • 20%
Under 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Below 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
Above 50% • 25%
Under 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Over 75% • 25%
Less than 30% • 25%
30% to 50% • 25%
51% to 70% • 25%
More than 70% • 25%
Below 30% • 25%
30% to 40% • 25%
40% to 50% • 25%
Above 50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
1-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
more than 30 countries • 25%
Low penetration (<1%) • 25%
Moderate penetration (1-3%) • 25%
High penetration (3-5%) • 25%
Very high penetration (>5%) • 25%
Achieve more than 15% market share • 25%
Achieve 10-15% market share • 25%
Achieve 5-10% market share • 25%
Achieve less than 5% market share • 25%